DC／CIK治疗对肺癌患者肝脏和肾脏的影响及护理干预

目的探讨树突状细胞／细胞因子诱导的杀伤细胞（DC／CIK）治疗对肝脏和肾脏的影响及护理干预。方法回顾性分析63例接受DC／CIK细胞治疗和同期接受化疗的70例晚期肺癌患者的临床资料。结果DC／CIK细胞治疗组有3例肝功能异常，发生率为4．7％，4例肾功能异常，发生率为6．3％；化疗组有14例肝功能异常，发生率为20．O％，16例肾功能异常，发生率为22．8％。两组相比，差异有统计学意义（P〈0．01）。结论与化疗相比，DC／CIK细胞治疗对肺癌患者的肝肾功能影响轻微，如早期给予护理干预，临床应用安全可靠。

The impact and nursing intervention of DC/CIK cell therapy on the liver and renal in patients with lung cancer

Objective To explore the impact and nursing intervention of the DC/CIK cell therapy on the liver and kidney in patients with lung cancer. Methods A retrospective liver and kidney function date analysis of 63 cases of lung cancer patients receiving DC/CIK cell therapy was done. At the same time, A retrospective liver and kidney function date analysis of 70 cases of lung cancer patients receiving chemotherapy was done. Results In the 63 patients receiving DC/CIK cell therapy, there were 3 cases of abnormal liver function and 4 cases of kidney dysfunction, the in- cidence rate is 4.7% and 6.3% respectively. There were 14 cases of abnormal liver function and 16 cases of renal dys- function in the 70 patients receiving chemotherapy, the incidence rate was 20.0% and 22.8% respectively. The differ- ence between two groups was significant （/9 〈 0.01）. Conclusion Compared with chemotherapy, the liver and kidney in patients with lung cancer are affected mildly by DC/CIK cell therapy. Taking early nursing intervention, clinical use of DC/CIK cell therapy is safe.